Dividend5 May 2026, 02:34 pm
Emcure Pharma Recommends ₹3.60 Final Dividend for FY26
AI Summary
Emcure Pharmaceuticals Ltd's Board of Directors has recommended a final dividend of ₹3.60 per equity share (36%) for the financial year ended March 31, 2026, subject to shareholder approval. The board also approved the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for one year and Mr. Satish Mehta as Managing Director for five years, both subject to member approval at the upcoming Annual General Meeting. Audited financial results for FY26 with an unmodified opinion from the statutory auditors were also approved.
Key Highlights
- Emcure Pharma recommends a final dividend of ₹3.60 per share for FY26.
- Re-appointment of Dr. Mukund Gurjar as Whole-time Director approved for one year.
- Mr. Satish Mehta's re-appointment as Managing Director approved for five years.
- Audited financial results for FY26 received an 'Unmodified Opinion' from auditors.
- Dividend payout is subject to shareholder approval at the AGM.
Price Impact
More from EMCURE